Search Results
Sep 03, 2026, 15:19 ET Longtime ALS Network supporter Tom Horton to paddle the Greek Islands honoring his late mother raising awareness and funds for people impacted by ALS in the U.S. and Greece
build greater awareness and momentum toward a world without the disease."We are deeply honored to join ALS Network in this collaboration," said Aspa Karampela, president of the Hellenic ALS Association. "Tom's expedition is a powerful reminder that compassion and determination know no borders. Together,
More news about: ALS Network
May 11, 2026, 08:14 ET Myrtelle to Present Clinical Data and Regulatory Progress for MYR-101 Gene Therapy Program at ASGCT 2026
www.myrtellegtx.com.About Canavan DiseaseCanavan disease (CD) is a fatal childhood genetic brain disease caused by mutations in the ASPA gene (ASPA) which prevent the normal expression of aspartoacylase, a critical enzyme produced in oligodendrocytes. The lack of normal aspartoacylase expression
More news about: Myrtelle, Inc
Oct 06, 2025, 08:18 ET Myrtelle Announces Presentation of Encouraging Interim Results from its Phase 1/2 Gene Therapy Trial for Canavan Disease at the 2025 Cell & Gene Meeting on the Mesa
About Canavan Disease Canavan disease (CD) is a fatal childhood genetic brain disease caused by mutations in the ASPA gene (ASPA) which prevent the normal expression of aspartoacylase, a critical enzyme produced in oligodendrocytes. The lack of normal aspartoacylase expression
More news about: Myrtelle, Inc
Sep 16, 2025, 08:11 ET Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
rAAV-Olig001-ASPA (MYR-101) is the first-ever recombinant AAV gene therapy designed to target oligodendrocytes, the brain cells responsible for producing myelin. The therapy directly addresses the enzymatic deficiency caused by mutations in the ASPA gene, which leads
More news about: Myrtelle, Inc